We did docking on Epidermal Growth Factor Receptor tyrosine kinase by downloading the crystal structure of the protein from Protein Data Bank as PDB ID: 1M17.pdb.For refine purpose we clean the protein by deleting the water atoms and pre-existing ligand erlotinib. Then we prepared the protein by taking CHARMM force fields. We choose the binding sites for the docking where preexisting standard ligand erlotinib situated on the protein. We prepared a sphere of radius 11.371639 Å around the pre-existing standard molecules binding region. The co-ordinates of that region are 21.315782, 0.511219, 52.441989.
Ligand Preparation:
We first drew the 2D version of standard molecules (Erlotinib) and compound 5b on Chembio office 2012 then convert this 2D into 3D on discovery studio 4.1 client. We applied force field MMFF on these molecules and perform energy minimization for both molecules by taking 1000 steps and maintain RMS gradient by 0.001 Å.
Docking Results:
Sl. No.
Molecule Name
Docking Score 
H-Bond Interaction

H-Bond Distance
Entropic Energy
Complex Entropy
Docking:
Then the prepared protein with generated sphere was taken for docking and energy minimized molecules were docked on the active sites by applying CAESAR conformation where maximum 255 conformations were allowed. Those conformations were prepared by performing 1000 steps. Docking tolerance was 0.25.
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Figure S1
1 H NMR spectra of 6,7-dimethoxy-N-(4-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5a):
S5
Figure S2
13 C NMR spectra of 6,7-dimethoxy-N-(4-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5a):
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Figure S3
1 H NMR spectra of 2-chloro-6,7-dimethoxy-N-(4-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5b):
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Figure S4
13 C NMR spectra of 2-chloro-6,7-dimethoxy-N-(4-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5b): 13 C NMR spectra of N-(4-((4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5f):
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Figure S13
1 H NMR spectra of (1-(4-(6,7-dimethoxyquinazolin-4-ylamino)benzyl)-1H-1,2,3-triazol-4-yl)methanol (5g):
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Figure S14
13 C NMR spectra of (1-(4-(6,7-dimethoxyquinazolin-4-ylamino)benzyl)-1H-1,2,3-triazol-4-yl)methanol (5g):
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Figure S15
1 H NMR spectra of (1-(4-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)benzyl)-1H-1,2,3-triazol-4-yl)methanol (5h):
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Figure S16
13 C NMR spectra of (1-(4-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)benzyl)-1H-1,2,3-triazol-4-yl)methanol (5h) :
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Figure S17
1 H NMR spectra of (1-(4-(quinazolin-4-ylamino)benzyl)-1H-1,2,3-triazol-4-yl)methanol (5i):
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Figure S18
13 C NMR spectra of (1-(4-(quinazolin-4-ylamino)benzyl)-1H-1,2,3-triazol-4-yl)methanol (5i) :
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Figure S19
1 H NMR spectra of 6,7-dimethoxy-N-(4-((4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5j): 
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Figure S20 13 C NMR spectra of 6,7-dimethoxy-N-(4-((4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5j):
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Figure S21 1 H NMR spectra of 2-chloro-6,7-dimethoxy-N-(4-((4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5k):
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Figure S22 13 C NMR spectra of 2-chloro-6,7-dimethoxy-N-(4-((4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5k):
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Figure S23 1 H NMR spectra of N-(4-((4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)quinazolin-4-amine (5l):
S27
Crystal Structure Data:
The crystal data of Compound 5b has already been deposited at Cambridge Crystallographic Data Centre. The CCDC reference number is 1854806. Figure S1 : Crystal structure of compound 5c 
